Fig. 3From: Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trialsThe pooled relative risk of the 50% response rate (defined as at least 50% reduction of headache attack frequency from baseline) in different treatment doses compared with placebo, the diamond indicates the estimated relative risk with 95% confidence interval for the pooled patients. RR relative riskBack to article page